Circulating Nucleic Acids

5316_NGS_QIAseq_cfDNA_700x233

A 4-part webinar series on cfDNA in liquid biopsy

Integrated collection, stabilization and purification for the cfDNA workflow Facing challenges in your circulating cell-free DNA (cfDNA) analysis? We have everything you need to gain deep insight into cfDNA: a complete and streamlined workflow covering blood sample collection and stabilization, cfDNA isolation, sequencing analysis and data interpretation. Attend the 4-part webinar series to learn about new technologies. See… Read article →


cfDNA_Discoveries_700x233

How to optimize the preanalytical portion of your circulating cell-free DNA (cfDNA) studies

Advances in liquid biopsy are allowing new strides in studies involving circulating cell-free DNA (cfDNA). With initial use in the prenatal testing field, cfDNA began to tell its story in fetal DNA genetic testing and has offered an alternative to the invasive and risk-prone amniocentesis. Now, it is breaking barriers in the field of cancer… Read article →


FertilityPregnancy_700x233

Peer into your child’s future – medically, not astrologically!

I’ve been following noninvasive prenatal testing (NIPT) technology very closely, as QIAGEN is becoming a pioneer in providing solutions for liquid biopsy-based research. Liquid biopsy is considered by many to have great potential in the future for predictive diagnostics. Recently, I came across an interesting news article on CNN Frontiers, focusing on the scientist who first discovered… Read article →


serum+plasma_miRNA_700x233

Analyzing fragmentation footprints in cell-free DNA

In the field of liquid biopsy, one of the challenges is identifying the cellular source of biological material. For example, current methods for analyzing circulating tumor DNA (ctDNA) rely upon genetic differences to distinguish ctDNA from cell-free DNA (cfDNA) released by normal cells. Because ctDNA represents only a small fraction of total circulating DNA, tumor-specific… Read article →


LiquidBiopsy_lncRNAExosomes_700x233

Tackle the challenges of circulating tumor DNA (ctDNA) research and non-invasive prenatal testing (NIPT)

At the frontier of liquid biopsy, NIPT (noninvasive prenatal testing) is increasingly being used to screen and test chromosomal abnormalities by analyzing cell-free fetal DNA circulating in maternal blood. Similarly, since disease-specific mutations or alterations of the circulating cell-free DNA (cfDNA) are frequently found in serum samples of cancer patients, research into cctDNA testing as… Read article →